NeurAxis Inc. to Showcase Innovations at Investor Healthcare Summit
NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a forward-thinking medical technology company, is focusing on accelerating the availability of neuromodulation therapies aimed at chronic and debilitating conditions impacting both children and adults. CEO Brian Carrico is gearing up to present a webcast at the Lytham Partners 2025 Investor Healthcare Summit, an event held virtually on January 13, 2025.
Event Details and Participation
The specially scheduled company presentation led by CEO Brian Carrico is set for 2:30 PM Eastern time. Attendees can access the webcast through the conference’s dedicated homepage. Furthermore, a replay of the presentation will be made available, allowing more individuals to engage with the content at their convenience.
Opportunity for One-on-One Meetings
NeurAxis also offers an exciting opportunity for personalized engagement post-event. Interested participants can arrange one-on-one meetings with the company, fostering deeper discussions about their innovative therapies. This direct communication can bolster investor relationships and provide insights into the company’s strategies.
About NeurAxis, Inc.
NeurAxis stands at the forefront of medical technology specializing in neuromodulation therapies. The Company is dedicated to developing and commercializing their patented IB-Stim™ therapy. This proprietary technology utilizes Percutaneous Electrical Nerve Field Stimulation (PENFS) which has gained FDA-clearance for treating functional abdominal pain, particularly associated with irritable bowel syndrome (IBS) in adolescents aged 11-18 years.
Continuing Innovation and Research
NeurAxis is committed to advancing scientific understanding and implementing evidence-based medicine practices. The Company is actively conducting additional clinical trials to explore the efficacy of PENFS in both pediatric and adult conditions that currently have significant unmet healthcare needs. Such advancements not only showcase the versatility of the technology but also its potential to provide relief to a broader patient population.
Investor Communication and Outreach
As NeurAxis continues its growth trajectory, maintaining open channels of communication with investors remains central to its strategy. The Company invites inquiries related to their therapies and future initiatives through their dedicated communication channels.
Contact Information for NeurAxis
Direct inquiries can be made to NeurAxis at info@neuraxis.com for further clarity regarding their innovative approaches and the upcoming presentation.
Frequently Asked Questions
What is NeurAxis, Inc. focused on?
NeurAxis is focused on developing neuromodulation therapies to address chronic conditions affecting patients of all ages.
When will the CEO's presentation take place?
The presentation by CEO Brian Carrico is scheduled for 2:30 PM Eastern time on January 13, 2025.
How can I access the event presentation?
Participants can access the event through the dedicated homepage of the conference or via linked reproduction available after the event.
What is the IB-Stim™ therapy?
IB-Stim™ is a neuromodulation therapy that utilizes PENFS technology, approved by the FDA for treating IBS-associated abdominal pain in adolescents.
How can I contact NeurAxis for more information?
You can contact NeurAxis through their email at info@neuraxis.com.
